Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Lenka Sedlarikova"'
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Inhibitors of B-cell receptor signaling, ibrutinib and idelalisib, and BCL-2 antagonist, venetoclax, have become the mainstay of treatment for chronic lymphocytic leukemia (CLL). Despite significant efficacy in most CLL patients, some patients develo
Externí odkaz:
https://doaj.org/article/7e4b32f8464f406cb9c64c48297cb66a
Autor:
Anna Petrackova, Michal Vasinek, Lenka Sedlarikova, Tereza Dyskova, Petra Schneiderova, Tomas Novosad, Tomas Papajik, Eva Kriegova
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
The insufficient standardization of diagnostic next-generation sequencing (NGS) still limits its implementation in clinical practice, with the correct detection of mutations at low variant allele frequencies (VAF) facing particular challenges. We add
Externí odkaz:
https://doaj.org/article/d76c193bd24a46b6b8a3a5b687a45983
Autor:
Lenka Sedlarikova, Lena Kubiczkova, Fedor Kryukov, Jana Pelcova, Zdenek Adam, Ludek Pour, Roman Hajek, Sabina Sevcikova
Publikováno v:
Biomedical Papers, Vol 159, Iss 4, Pp 554-561 (2015)
Aims: Multiple myeloma (MM), the second most common hematological cancer, is a lymphoproliferative disease of terminally differentiated B lymphocytes characterized by expansion of monoclonal plasma cells. With the introduction of new drugs, MM has be
Externí odkaz:
https://doaj.org/article/979666c699f247469def1d8d33f8a5fc
Autor:
Sabina Sevcikova, Helena Paszekova, Lenka Besse, Lenka Sedlarikova, Veronika Kubaczkova, Martina Almasi, Ludek Pour, Roman Hajek
Publikováno v:
Biomedical Papers, Vol 159, Iss 2, Pp 288-293 (2015)
Background: Multiple myeloma (MM) is characterized by malignant proliferation of plasma cells (PC) which accumulate in the bone marrow (BM). The advent of new drugs has changed the course of the disease from incurable to treatable, but most patients
Externí odkaz:
https://doaj.org/article/bdd4b12404aa4c73a5c883b3899fd0dc
Publikováno v:
Biomedical Papers, Vol 159, Iss 2, Pp 184-191 (2015)
Background: MicroRNAs are short non-coding regulators of gene expression. The human miR-29 family consists of three members: miR-29a, miR-29b and miR-29c. Members of this family were found to be aberrantly expressed in various types of tumors, includ
Externí odkaz:
https://doaj.org/article/05e88df5880f404bb34f870aa55c6c60
Autor:
Lenka Besse, Lenka Sedlarikova, Fedor Kryukov, Jana Nekvindova, Lenka Radova, Ondrej Slaby, Petr Kuglik, Martina Almasi, Miroslav Penka, Marta Krejci, Zdenek Adam, Ludek Pour, Sabina Sevcikova, Roman Hajek
Publikováno v:
PLoS ONE, Vol 10, Iss 9, p e0137294 (2015)
Poor outcome of extramedullary disease in multiple myeloma patients and lack of outcome predictors prompt continued search for new markers of the disease. In this report, we show circulating microRNA distinguishing multiple myeloma patients with extr
Externí odkaz:
https://doaj.org/article/1c18f8435a574f45a2322070f78e88ad
Autor:
Viera Sandecká, Lucie Rihova, Lenka Besse, Jiri Jarkovsky, Sabina Ševčíková, Ludek Pour, Veronika Kubaczková, Tomas Jelinek, Hana Plonkova, Lucie Brožová, Renata Bezdekova, Roman Hájek, Lenka Sedlarikova, David Vrabel, Martin Stork, Martina Almáši
Publikováno v:
European Journal of Haematology
Objectives Progress in multiple myeloma treatment allows patients to achieve deeper responses, for which the assessment of minimal residual disease (MRD) is critical. Typically, bone marrow samples are used for this purpose; however, this approach is
Autor:
Aleš Obr, Adela Berkova, Nela Kasalova, Eva Kriegova, Tomas Papajik, Kristina Forsterova, Helena Urbankova, Anna Petrackova, Zuzana Zemanova, Marek Trneny, Diana Malarikova, Tomáš Fürst, Pavel Klener, Lenka Sedlarikova, Andrea Jirkuvová, Barbora Cudova
Publikováno v:
British journal of haematologyReferences. 191(5)
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Frontiers in Oncology
Frontiers in Oncology
Inhibitors of B-cell receptor signaling, ibrutinib and idelalisib, and BCL-2 antagonist, venetoclax, have become the mainstay of treatment for chronic lymphocytic leukemia (CLL). Despite significant efficacy in most CLL patients, some patients develo
Autor:
Tereza Libigerova, Lenka Sedlarikova, Alzbeta Hamplova, Jiri Minarik, Tomas Pika, Eva Kriegova, Petra Krhovska, Anna Petrackova, Tomas Papajik, Jana Balcarkova
Publikováno v:
British journal of haematologyReferences. 189(4)